



RECEIVED
JAN 28 2003
TECH CENTER 1600/2800

PATENTS
Attorney Docket No. VOS-27

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Karin Molling et al.
Application No. : 10/047,539 Confirmation No. : 4984
Filed : January 15, 2002
For : PHARMACEUTICAL COMPOSITIONS FOR TREATING
OR PREVENTING CANCER
Group Art Unit : 1633
Examiner : Not yet assigned

New York, New York 10020
January 21, 2003

Hon. Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants,
through their representatives, make of record the following
documents:*

United States Patent

<u>Patentee</u>	<u>Patent No.</u>	<u>Issue Date</u>
Kawakami et al.	5,844,075	December 1, 1998

* A completed Form PTO-1449 listing these documents is
attached hereto.

Other Documents

Nawrath, M., et al., "Reduced Melanoma Tumor Formation in Mice Immunized with DNA Expressing the Melanoma - Specific Antigen gp100/pmell17," *Leukemia*, 13:S48-S51 (1999).

Rosenberg, S.A., "Cancer Vaccines Based on the Identification of Genes Encoding Cancer Regression Antigens," *Immunology Today*, 18:175-182 (1997).

Schreurs, M.W.J., et al., "Genetic Vaccination Against the Melanocyte Lineage-specific Antigen gp100 Induces Cytotoxic T Lymphocyte-mediated Tumor Protection," *Cancer Research*, 58:2509-2514 (1998).

Pursuant to 37 C.F.R. § 1.97(e)(1), the undersigned certifies that each of the documents listed in this Information Disclosure Statement was cited in a December 12, 2002 European Search Report of European Application No. EP 02 00 0185 ("the European Search Report"), the European counterpart of the above-identified application.

The European Search Report was mailed not more than three months prior to the filing of this statement. A copy of the European Search Report is submitted herewith.

Applicant respectfully requests that these documents be (1) considered by the Examiner prior to issuance of any patent from this application; and (2) printed on any patent that may issue from this application. Applicant also requests that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.

Respectfully submitted,





James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Karen E. Brown (Reg. No. 43,866)
Greg A. Morris (Reg. No. P-53,349)
Agents for Applicants
FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax: (212) 596-9090

I Hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to:
COMMISSIONER FOR
PATENTS P.O. BOX 2007
ARLINGTON, VA 22202 on

January 21, 2003

Lillian Garcia


Signature of Person Signing



FORM PTO-1449 U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTS

ATTY. DOCKET NO.
VOS-27

APPLICATION NO.
10/047,539

APPLICANTS
Karin Mölling et al.

CONFIRMATION NO.
4984

FILING DATE
January 15, 2002

GROUP
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,844,075	12/01/98	Kawakami et al.	530	326	
RECEIVED JAN 28 2003 TECH CENTER 1600/2900						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Nawrath, M., et al., "Reduced Melanoma Tumor Formation in Mice Immunized with DNA Expressing the Melanoma - Specific Antigen gp100/pmel17," <i>Leukemia</i> , 13:S48-S51 (1999).
	Rosenberg, S.A., "Cancer Vaccines Based on the Identification of Genes Encoding Cancer Regression Antigens," <i>Immunology Today</i> , 18:175-182 (1997).
	Schreurs, M.W.J., et al., "Genetic Vaccination Against the Melanocyte Lineage-specific Antigen gp100 Induces Cytotoxic T Lymphocyte-mediated Tumor Protection," <i>Cancer Research</i> , 58:2509-2514 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



RECEIVED

JAN 28 2003

TECH CENTER 1600/2900

#6
1633 dia
3/3/03

PATENTS

Attorney Docket No. VOS-27

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Karin Molling et al.
Application No. : 10/047,539 Confirmation No. : 4984
Filed : January 15, 2002
For : PHARMACEUTICAL COMPOSITIONS FOR TREATING
OR PREVENTING CANCER
Group Art Unit : 1633
Examiner : Not yet assigned

New York, New York 10020
January 21, 2003

Hon. Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted more than three months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97(b)(3), submission of this Statement requires no fee. However, in the event that the first Office Action on the merits has been issued, this Statement is accompanied

by a certification as required under 37 C.F.R. §§ 1.97(c)(1) and 1.97(e)(1). Thus, no fee is required.

If for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.


Respectfully submitted,




James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Karen E. Brown (Reg. No. 43,866)
Greg A. Morris (Reg. No. P-53,349)
Agents for Applicants
FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax: (212) 596-9090

I Heroby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to:
COMMISSIONER FOR
PATENTS P.O. BOX 2327
ARLINGTON, VA 22202 on

January 21, 2003
Lillian Garcia


Signature of Person Signing



PTO-1449 U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTS

ATTY. DOCKET NO.
VOS-27

APPLICANTS
Karin Mölling et al.

FILING DATE
January 15, 2002

APPLICATION NO.
10/047,539

CONFIRMATION NO.
4984

GROUP
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,844,075	12/01/98	Kawakami et al.	530	326	
RECEIVED JAN 28 2003 TECH CENTER 1600/2900						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Nawrath, M., et al., "Reduced Melanoma Tumor Formation in Mice Immunized with DNA Expressing the Melanoma - Specific Antigen gp100/pmel17," <i>Leukemia</i> , 13:S48-S51 (1999).
	Rosenberg, S.A., "Cancer Vaccines Based on the Identification of Genes Encoding Cancer Regression Antigens," <i>Immunology Today</i> , 18:175-182 (1997).
	Schreurs, M.W.J., et al., "Genetic Vaccination Against the Melanocyte Lineage-specific Antigen gp100 Induces Cytotoxic T Lymphocyte-mediated Tumor Protection," <i>Cancer Research</i> , 58:2509-2514 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.